|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
on1337944361 |
| 003 |
OCoLC |
| 005 |
20241006213017.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
220806s2022 si o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d GW5XE
|d YDX
|d EBLCP
|d OCLCQ
|d CASUM
|d OCLCO
|d OCLCL
|d OCLCF
|d OCLCO
|d N$T
|d SFB
|d OCLCO
|
| 019 |
|
|
|a 1337856446
|
| 020 |
|
|
|a 9789811926150
|q (electronic bk.)
|
| 020 |
|
|
|a 9811926158
|q (electronic bk.)
|
| 020 |
|
|
|z 981192614X
|
| 020 |
|
|
|z 9789811926143
|
| 024 |
7 |
|
|a 10.1007/978-981-19-2615-0
|2 doi
|
| 035 |
|
|
|a (OCoLC)1337944361
|z (OCoLC)1337856446
|
| 050 |
|
4 |
|a RC848.C5
|
| 072 |
|
7 |
|a MED045000
|2 bisacsh
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Pharmacotherapy for liver cirrhosis and its complications /
|c Xingshun Qi, Yongping Yang, editors.
|
| 260 |
|
|
|a Singapore :
|b Springer,
|c 2022.
|
| 300 |
|
|
|a 1 online resource (245 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Anti-HBV drugs in liver cirrhosis -- Anti-HCV drugs in liver cirrhosis -- Anticoagulants in liver cirrhosis -- Antibiotics in liver cirrhosis -- Silymarin in liver cirrhosis -- Ursodeoxycholic acid in liver cirrhosis -- Emricasan in liver cirrhosis -- Non-selective beta blockers in liver cirrhosis -- Somatostatin and octreotide in liver cirrhosis -- Terlipressin in liver cirrhosis -- Diuretics in liver cirrhosis -- Statins in liver cirrhosis -- L-Ornithine L-Aspartate in liver cirrhosis -- Lactulose in liver cirrhosis.
|
| 520 |
|
|
|a This book aims to provide an updated information on different types of major and emerging drugs for managing liver cirrhosis and its complications, including acute gastroesophageal variceal bleeding, ascites, hepatic encephalopathy, liver failure, acute kidney injury, and portal venous thrombosis. The chapters are organized by drug class, such as anti-HBV drugs, anti-HCV drugs, anticoagulants, and antibiotics, etc. The clinical efficacy, indication, and contra-indication of the various drug therapies are discussed using supportive reference material from authoritative sources and published clinical trials. It will be an invaluable reference for physicians who are treating patients with liver cirrhosis, especially those presenting with acute life-threatening complications.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (SpringerLink, viewed August 9, 2022).
|
| 650 |
|
0 |
|a Liver
|x Cirrhosis
|x Chemotherapy.
|
| 650 |
|
0 |
|a Liver
|x Cirrhosis
|x Chemotherapy
|x Complications.
|
| 650 |
|
0 |
|a Chemotherapy.
|
| 650 |
|
0 |
|a Liver
|x Cirrhosis.
|
| 650 |
|
7 |
|a Chemotherapy
|2 fast
|
| 650 |
|
7 |
|a Cirrosi hepàtica.
|2 thub
|
| 650 |
|
7 |
|a Quimioteràpia.
|2 thub
|
| 655 |
|
7 |
|a Llibres electrònics.
|2 thub
|
| 700 |
1 |
|
|a Qi, Xingshun,
|d 1984-
|1 https://id.oclc.org/worldcat/entity/E39PCjFpcyRMvrKjyXHCX3qXJP
|
| 700 |
1 |
|
|a Yang, Yongping.
|1 https://id.oclc.org/worldcat/entity/E39PCjJtCT4c8vJv9Hbpv9QQFX
|
| 776 |
0 |
8 |
|i Print version:
|a Qi, Xingshun.
|t Pharmacotherapy for Liver Cirrhosis and Its Complications.
|d Singapore : Springer, ©2022
|z 9789811926143
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://link.springer.com/10.1007/978-981-19-2615-0
|y Click for online access
|
| 903 |
|
|
|a SPRING-MED2022
|
| 994 |
|
|
|a 92
|b HCD
|